Nuvalent joins the IPO party less than 6 months after launch, while Icosavax kicks its 'soccer ball' VLPs to Nasdaq
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
Less than six months after emerging from stealth, the Deerfield-backed biotech Nuvalent is already prepping a jump to Nasdaq. And it’s a leap that could prove highly profitable for the blue chip firm.
Nuvalent filed its S-1 paperwork Wednesday, penciling in the $100 million raise estimate that’s become commonplace during the IPO boom of the last 15 or so months. The final figure may end up higher given the biotech’s crossover raise in May hit the $135 million mark, but even if it falls short, it’s a rapid ascent for Nuvalent after its January debut.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.